CSIMarket
 


Johnson and Johnson  (JNJ)
Other Ticker:  
 
 

JNJ's Capital Expenditures Growth by Quarter and Year

Johnson And Johnson's Capital Expenditures results by quarter and year




JNJ Capital Expenditures (in millions $) FY 2020 FY 2019 FY 2018 FY 2017
IV Quarter December - 1,260.00 1,318.00 1,240.00
III Quarter September - 745.00 819.00 790.00
II Quarter June - 837.00 875.00 689.00
I Quarter March 625.00 656.00 658.00 560.00
FY   625.00 3,498.00 3,670.00 3,279.00



JNJ Capital Expenditures first quarter 2020 Y/Y Growth Comment
Johnson And Johnson reported decrease in Capital Expenditures in the first quarter by -4.73% to $ 625.00 millions, from the same quarter in 2019.
Despite modest results in the first quarter, contraction in Johnson And Johnson's Capital Expenditures appears to be smaller than Company's recent average decline.

Looking into first quarter results within Major Pharmaceutical Preparations industry 83 other companies have achieved higher Capital Expenditures growth. While Johnson And Johnson' s Capital Expenditures decline of -4.73% ranks overall at the positon no. 1389 in the first quarter.




JNJ Capital Expenditures ( Y/Y Growth %) 2020
2019 2018 2017
IV Quarter December - -4.4 % 6.29 % 13.45 %
III Quarter September - -9.04 % 3.67 % 7.19 %
II Quarter June - -4.34 % 27 % -8.98 %
I Quarter March -4.73 % -0.3 % 17.5 % -12.36 %
FY   - -4.69 % 11.92 % 1.64 %

Financial Statements
Johnson And Johnson's first quarter 2020 Capital Expenditures $ 625.00 millions JNJ's Income Statement
Johnson And Johnson's first quarter 2019 Capital Expenditures $ 656.00 millions Quarterly JNJ's Income Statement
New: More JNJ's historic Capital Expenditures Growth >>


JNJ Capital Expenditures (Quarter on Quarter Growth %)

2020
2019 2018 2017
IV Quarter December - 69.13 % 60.93 % 56.96 %
III Quarter September - -10.99 % -6.4 % 14.66 %
II Quarter June - 27.59 % 32.98 % 23.04 %
I Quarter March -50.4 % -50.23 % -46.94 % -48.76 %
FY (Year on Year)   - -4.69 % 11.92 % 1.64 %




Capital Expenditures first quarter 2020 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #84
Healthcare Sector #260
Overall #1389

Capital Expenditures Y/Y Growth Statistics
High Average Low
28.93 % -5.3 % -100 %
(June 30. 2013)   (Jan 01 2012)
Capital Expenditures first quarter 2020 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #84
Healthcare Sector #260
Overall #1389
Capital Expenditures Y/Y Growth Statistics
High Average Low
28.93 % -5.3 % -100 %
(June 30. 2013)   (Jan 01 2012)

Capital Expenditures by Quarter for the Fiscal Years 2017, 2018, 2019, 2020

Johnson And Johnson's Q/Q Capital Expenditures Growth


Capital Expenditures Q/Q Growth Statistics
High Average Low
174.48 % 14.62 % -100 %
(Dec. 30. 2011)  


JNJ's I. Quarter Q/Q Capital Expenditures Comment
In the I. Quarter 2020 Johnson And Johnson reported fall in Capital Expenditures sequentially by -50.4% to $ 625.00 millions, from $ 1,260.00 millions released in the previous reporting period.

But that's not huge problem, as Johnson And Johnson's Capital Expenditures generally gravitate to dip in this quarter.

Within Major Pharmaceutical Preparations industry 9 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Johnson And Johnson's Capital Expenditures growth quarter on quarter, overall rank is 348.


Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #10
Healthcare Sector #34
Overall #348
Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #10
Healthcare Sector #34
Overall #348
Capital Expenditures Q/Q Growth Statistics
High Average Low
174.48 % 14.62 % -100 %
(Dec. 30. 2011)  


JNJ's I. Quarter Q/Q Capital Expenditures Comment
In the I. Quarter 2020 Johnson And Johnson reported fall in Capital Expenditures from the previous quarter by -50.4% to $ 625.00 millions, from $ 1,260.00 millions declared in the previous qaurter.

If you evaluate current slump in the I. Quarter 2020, you suppose to presume, that commonly I. Quarter performance appear to be softer in contrast to the preciding period

Within Major Pharmaceutical Preparations industry 9 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Johnson And Johnson's Capital Expenditures growth quarter on quarter, overall rank is 348.


Johnson And Johnson's 12 Months Capital Expenditures Growth Year on Year


Capital Expenditures TTM Growth

12 Months Ending
(Mar 29 2020)
12 Months Ending
(Dec 29 2019)
12 Months Ending
(Sep 29 2019)
12 Months Ending
(Jun 30 2019)
12 Months Ending
(Mar 31 2019)
Cumulative Capital Expenditures 12 Months Ending $ 3,467.00 $ 3,498.00 $ 3,556.00 $ 3,630.00 $ 3,668.00
Y / Y Capital Expenditures Growth (TTM) -5.48 % -4.69 % -1 % 1.88 % 8.62 %
Year on Year Capital Expenditures Growth Overall Ranking # 1499 # 1867 # 1394 # 1549 # 1460
Seqeuential Capital Expenditures Change (TTM) -0.89 % -1.63 % -2.04 % -1.04 % -0.05 %
Seq. Capital Expenditures Growth (TTM) Overall Ranking # 1371 # 1777 # 1615 # 1666 # 1624




Cumulative Capital Expenditures growth Comment
Johnson And Johnson's cumulative 12 months Capital Expenditures continue to decrease, but on the faster rate at -5.48% year on year, at Mar 29 2020 compare to the -4.69% decrease at Dec 29 2019. If the Johnson And Johnson's fiscal year would end at Mar 29 2020, annual Capital Expenditures would be $3,467 millions.

In the Healthcare sector 229 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Total ranking has impoved so far to 1499, from total ranking in previous quarter at 1867.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
694.28 %
20.19 %
-7.8 %
 

Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 78
Healthcare Sector # 230
Overall # 1499

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
661.98 %
23.06 %
-13.29 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 78
Sector # 247
S&P 500 # 1371
Cumulative Capital Expenditures growth Comment
Johnson And Johnson's cumulative 12 months Capital Expenditures continue to decrease, but on the faster rate at -5.48% year on year, at Mar 29 2020 compare to the -4.69% decrease at Dec 29 2019. If the Johnson And Johnson's fiscal year would end at Mar 29 2020, annual Capital Expenditures would be $3,467 millions.

In the Healthcare sector 229 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Total ranking has impoved so far to 1499, from total ranking in previous quarter at 1867.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
694.28 %
20.19 %
-7.8 %
 


Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 78
Healthcare Sector # 230
Overall # 1499

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
661.98 %
23.06 %
-13.29 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 78
Sector # 247
S&P 500 # 1371




Other Capital Expenditures Growth
Major Pharmaceutical Preparations Industry Capital Expenditures Growth Trends and Statistics
Healthcare Sector Capital Expenditures Growth Statistics
Capital Expenditures Growth Trends for overall market
JNJ's Capital Expenditures Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Capital Expenditures Growth
Lowest Ranking Capital Expenditures Growth
Capital Expenditures Growth for JNJ's Competitors
Capital Expenditures Growth for Johnson And Johnson's Suppliers
Capital Expenditures Growth for JNJ's Customers

You may also want to know
JNJ's Annual Growth Rates JNJ's Profitability Ratios JNJ's Asset Turnover Ratio JNJ's Dividend Growth
JNJ's Roe JNJ's Valuation Ratios JNJ's Financial Strength Ratios JNJ's Dividend Payout Ratio
JNJ's Roa JNJ's Inventory Turnover Ratio JNJ's Growth Rates JNJ's Dividend Comparisons



Companies with similar Capital Expenditures decrease for the quarter ending Mar 29 2020 within Healthcare SectorY/Y Change %Capital Expenditures for the quarter ending Mar 29 2020
Orasure Technologies Inc -1.26 %$ -1.256 millions
Beigene Ltd -1.35 %$ -1.351 millions
Spero Therapeutics Inc -2.47 %$ -2.469 millions
Neuronetics Inc -2.92 %$ -2.920 millions
Myriad Genetics Inc -3.23 %$ -3.226 millions
Celcuity Inc -4.28 %$ -4.276 millions
Kaleido Biosciences Inc -4.53 %$ -4.529 millions
Standard Diversified Inc -4.67 %$ -4.674 millions
Johnson and Johnson -4.73 %$ -4.726 millions
Fibrogen Inc -4.97 %$ -4.969 millions
Vanda Pharmaceuticals Inc -5.09 %$ -5.089 millions
Tenet Healthcare Corp -5.15 %$ -5.155 millions
Hanger Inc -5.38 %$ -5.379 millions
Biolife Solutions Inc -6.41 %$ -6.410 millions
Endologix Inc -6.54 %$ -6.542 millions
Intuitive Surgical Inc -8.36 %$ -8.362 millions
Bristol Myers Squibb Co -8.82 %$ -8.824 millions
Dynatronics Corp -8.92 %$ -8.923 millions
Integrated Biopharma Inc -9.52 %$ -9.524 millions
Viveve Medical Inc -10.06 %$ -10.056 millions
Heska Corp -10.26 %$ -10.256 millions
Icu Medical Inc -10.45 %$ -10.447 millions
Milestone Scientific Inc -11.92 %$ -11.920 millions
Veracyte Inc -13.07 %$ -13.072 millions
Baxter International Inc -13.13 %$ -13.131 millions
Eventbrite Inc -13.22 %$ -13.215 millions
Blueprint Medicines Corporation -13.84 %$ -13.842 millions
Dexcom Inc -15.52 %$ -15.522 millions
Mettler Toledo International Inc -15.93 %$ -15.930 millions
Teleflex Incorporated -16.22 %$ -16.217 millions


             
Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

WEYL's Profile

Stock Price

WEYL's Financials

Business Description

Fundamentals

Charts & Quotes

WEYL's News

Suppliers

WEYL's Competitors

Customers & Markets

Economic Indicators

WEYL's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Indices

Sectors & Industries

Financials

Commodities

Currencies

News


At a Glance

Stocks

Economy

Industries

Other

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.  Free Stock Market News Feeds
   Copyright © 2020 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

To view Intraday Stock Data Java must be installed. Java content may be prohibited by the security software, to see the stock quotes, choose "allow content from this page" option. Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071